GENFERON 500 000 IU COMBINED INTERFERON BASED IMMUNOMODULATOR (10 sup)

GENFERON 500 000 IU COMBINED INTERFERON BASED IMMUNOMODULATOR is an immunomodulating preparation with antiviral, antibacterial, antiproliferative, and immune-supporting properties.

Indications:

• Used as part of complex therapy for infectious and inflammatory disorders of the urogenital tract in adults, including genital herpes, chlamydia, ureaplasmosis, mycoplasmosis, recurrent vaginal candidiasis, gardnerellosis, trichomoniasis, human papillomavirus infection, bacterial vaginosis, cervical erosion, cervicitis, vulvovaginitis, bartholinitis, adnexitis, prostatitis, urethritis, balanitis, and balanoposthitis.
• Used in combination therapy for acute bronchitis in adults.
• Used in combination therapy for chronic recurrent bacterial cystitis in adults.
• Used in combination therapy for chronic endometritis in adults.

Ingredients:

COMPOSITION PER SUPPOSITORY

Active substances: recombinant human interferon alpha-2b 500,000 IU; taurine – 0.01 g; benzocaine – 0.055 g;

Additional ingredients: hard fat base – sufficient for a suppository weighing 1.65 g, dextran 60,000 – 0.0015 g, macrogol 1500 – 0.1240 g, polysorbate 80 – 0.0330 g, emulsifier T2 – 0.1320 g, sodium hydrogen citrate – 0.0001 g, citric acid – 0.0015 g, purified water – 0.0660 g.

Pharmacological action:

GENFERON® is a combined medication whose therapeutic activity is based on the properties of its active ingredients. It provides both local and systemic effects.
Genferon® contains recombinant human interferon alpha-2b obtained using genetically modified Escherichia coli bacteria carrying the human interferon alpha-2b gene.
Interferon alpha-2b demonstrates antiviral, immunomodulatory, antibacterial, and antiproliferative activity. Its antiviral action is associated with activation of intracellular enzymes that suppress viral replication. The immunomodulatory effect is mainly expressed through stimulation of cellular immune responses, increasing the body’s defense against viruses, intracellular pathogens, and tumor-transformed cells. This occurs through activation of CD8+ T-lymphocytes and NK cells, enhancement of B-cell differentiation and antibody synthesis, stimulation of the monocyte-macrophage system and phagocytosis, and increased expression of major histocompatibility complex class I molecules, improving recognition of infected cells by the immune system. Interferon also activates leukocytes within mucosal layers, promoting elimination of pathological lesions, and restores secretory immunoglobulin A production. The antibacterial effect results from enhanced immune responses stimulated by interferon.
Taurine supports tissue repair and normalization of metabolic processes while providing membrane-protective and immunomodulatory effects. As a strong antioxidant, taurine neutralizes reactive oxygen species, excessive accumulation of which contributes to pathological conditions. Taurine also helps maintain interferon biological activity, increasing the therapeutic effectiveness of the medication. Benzocaine (anesthesin) is a local anesthetic that reduces sodium ion permeability in cell membranes, displaces calcium ions from membrane receptors, and blocks nerve impulse transmission. It prevents the formation and conduction of pain signals in sensory nerve endings. Benzocaine acts locally and is not absorbed into systemic circulation.

Directions for use and dosage:

• INFECTIOUS AND INFLAMMATORY UROGENITAL DISEASES IN WOMEN.
  Administer 1 suppository (250,000 IU, 500,000 IU, or 1,000,000 IU depending on disease severity) vaginally or rectally twice daily for 10 days. In prolonged conditions, use 1 suppository three times weekly every other day for 1–3 months. In severe vaginal infections, 1 suppository 500,000 IU may be used intravaginally in the morning and 1 suppository 1,000,000 IU rectally at bedtime together with antibacterial or antifungal therapy. To restore local immunity during treatment of infectious and inflammatory urogenital diseases in pregnant women at 13–40 weeks of pregnancy, use one 250,000 IU suppository vaginally twice daily for 10 days.
• INFECTIOUS AND INFLAMMATORY UROGENITAL DISEASES IN MEN.
  Use rectally: 1 suppository (500,000 IU or 1,000,000 IU depending on disease severity) twice daily for 10 days.
• AS PART OF COMBINATION THERAPY FOR ACUTE BRONCHITIS IN ADULTS.
  1 suppository (1,000,000 IU) rectally twice daily for 5 days.
• AS PART OF COMBINATION THERAPY FOR CHRONIC RECURRENT BACTERIAL CYSTITIS IN ADULTS.
  During exacerbation: 1 suppository (1,000,000 IU) rectally twice daily for 10 days together with standard antibacterial treatment, followed by 1 suppository (1,000,000 IU) rectally every other day for 40 days to reduce recurrence risk.
• AS PART OF COMBINATION THERAPY FOR CHRONIC ENDOMETRITIS IN ADULTS.
  Use 1 suppository (1,000,000 IU) rectally twice daily for 10 days, then 1 suppository (500,000 IU) rectally twice daily for 10 days, followed by 1 suppository (1,000,000 IU) rectally every other day for 10 days.

Contraindications:

Hypersensitivity to interferon or any other component of the medication.

Special instructions:

To avoid reinfection of the urogenital tract, simultaneous treatment of the sexual partner is recommended.
The medication may be used during menstruation.
GENFERON® does not affect the ability to perform activities requiring increased attention and rapid reactions, including driving or operating machinery.
The medication may be prescribed to restore local immunity during pregnancy (13–40 weeks) as part of combination treatment for genital herpes, chlamydia, ureaplasmosis, mycoplasmosis, cytomegalovirus infection, human papillomavirus infection, and bacterial vaginosis accompanied by itching, discomfort, and pain in the lower urogenital tract. Clinical studies confirmed the safety of intravaginal administration of Genferon® 250,000 IU during pregnancy from 13 to 40 weeks. Safety during the first trimester has not been established.
Use with caution in cases of exacerbation of allergic or autoimmune diseases.
The medication does not impair the ability to perform potentially hazardous activities requiring concentration and rapid psychomotor responses.

Packaging and release form:

Vaginal and rectal suppositories, 500,000 IU - 10 suppositories per pack with instructions for medical use.

Storage temperature: from 2℃ to 8℃

Guaranteed authenticity and quality:

100% Original from BIOCAD (Russian Federation)

BIOCAD is one of Russia’s leading biotechnology companies, delivering a complete cycle of preparation research, development, and manufacturing for the treatment of cancer, autoimmune, and genetic diseases.

BIOCAD manages the full pharmaceutical development process: from molecular discovery and genetic engineering to large-scale production.

Development and production:

BIOCAD